Sodium thiosulfate for prevention of hearing loss in children receiving cisplatin chemotherapy
SUMMARY NIHR HSC ID: 7091
Sodium thiosulfate is intended to be used to prevent hearing loss in children who receive cisplatin chemotherapy. It inactivates platinum complexes by binding electrophilic platinium with thiol, thus forming a covalent complex that is not cytotoxic and can be excreted rapidly. Sodium thiosulfate does not currently have Marketing Authorisation in the EU for any indication.
Cancer in children (aged 0-14 years) is rare compared with the adult population, accounting for less than 1% of all cancers. Cisplatin is a widelyused chemotherapeutic agent and is standard of care for a variety of paediatric malignancies. All children who receive cisplatin are at risk of cisplatin-induced hearing loss, and it occurs in at least 60% of treated patients. Hearing loss is likely to delay speech and language development in children and can have a significant impact on school performance and psychosocial functioning.
There are currently no treatment options available to prevent hearing loss in children receiving cisplatin chemotherapy. Sodium thiosulfate is currently in phase III clinical trials investigating its effect on hearing loss when administered alongside cisplatin chemotherapy. These trials are expected to complete in late 2015 and late 2017. 
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INNOVATION and/or ADVANTAGES
If licensed, sodium thiosulfate will provide a treatment option for this patient group for whom there are currently no curative or preventative treatments available.
DEVELOPER
Fennec Pharmaceuticals.
AVAILABILITY, LAUNCH OR MARKETING
In phase III clinical trials.
PATIENT GROUP BACKGROUND
Cisplatin is a widely-used chemotherapeutic agent and is standard of care for a variety of paediatric malignancies, including osteosarcoma, neuroblastoma, medulloblastoma, hepatoblastoma and germ cell tumours 3, 4 . However, one of the most important adverse effects is the occurrence of hearing loss (ototoxicity), which is characterised by bilateral, high frequency sensorineural hearing loss, and is often accompanied by tinnitus and vertigo 3.5 . It is permanent and occasionally has delayed onset, with progressive loss occurring many years after completion of therapy 6 . The hearing loss is caused by sensory hair cell destruction that begins at the base of the cochlea, where high frequency sounds are processed, and continues toward the cochlear apex, where lower frequency sounds are affected 6 . Hearing loss is likely to delay speech and language development in children and can have a significant impact on school performance and psychosocial functioning 6, 7 . 
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NHS or GOVERNMENT PRIORITY AREA
CLINICAL NEED and BURDEN OF DISEASE
Cancer in children (aged 0-14 years) is rare compared with the adult population, accounting for less than 1% of all cancers 8 . In England, the average number of new cases per year between 2009 and 2011 was 1,328, representing a World age-standardised incidence rate of around 145 per million population 9 . All children receiving cisplatin are at risk of cisplatininduced ototoxicity a , and it occurs in at least 60% of paediatric patients 3, 10 . However, incidence varies according to patient group, dose received, patient age, and the criteria by which hearing impairment is defined 11 , with reported rates ranging from 13-96% 3 . The population likely to be eligible to receive sodium thiosulfate could not be estimated from available published sources.
PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance
• NICE quality standard. Children and young people with cancer (QS55). February 2014.
• NICE guidance on cancer services. Improving outcomes in children and young people with cancer (CSGCYP 
CURRENT TREATMENT OPTIONS
There are currently no treatment options available to prevent loss of hearing in children receiving cisplatin chemotherapy. Co-treatment with other potentially ototoxic drugs, cranial irradiation, age of <5 years and male sex increases the risk of cisplatin-induced ototoxicity 3 . The dose and dosing schedule is also a risk factor, with high cumulative dose, high dose per a Expert personal opinion.
course and bolus application being high risk, although a threshold has not been identified below which cisplatin-induced ototoxicity is absent 3 . 
EFFICACY and SAFETY
ESTIMATED COST and IMPACT
COST
The cost of sodium thiosulfate is not yet known.
IMPACT -SPECULATIVE Impact on Patients and Carers
 Reduced mortality/increased length of survival  Reduced symptoms or disability 
